{
    "clinical_study": {
        "@rank": "65561", 
        "acronym": "VICTORIA", 
        "arm_group": [
            {
                "arm_group_label": "vinflunine plus gemcitabine", 
                "arm_group_type": "Experimental", 
                "description": "vinflunine 320 mg/m\u00b2 D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks"
            }, 
            {
                "arm_group_label": "paclitaxel plus gemcitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "paclitaxel 175 mg/m\u00b2 D1 followed by Gemcitabine 1250 mg/m\u00b2 D1 and D8 every 3 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The combination of vinflunine and gemcitabine in advanced breast cancer in comparison to\n      paclitaxel and gemcitabine is based on the following points: the significant antitumour\n      activity of vinflunine in metastatic breast cancer (MBC) as single agent after\n      anthracycline-taxane exposure and recent phase I study results of the vinflunine plus\n      gemcitabine is at least additive and both drugs have a distinct mechanism of action; since\n      taxanes have been approved in the adjuvant setting and are widely used in the treatment of\n      early breast cancer it is worthwhile to assess new combination chemotherapy regimens as\n      first line therapy for metastatic breast cancer."
        }, 
        "brief_title": "A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": "Advanced Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  female patients\n\n          -  18 years or older but less than 75 years old\n\n          -  histologically/cytologically confirmed breast cancer\n\n          -  documented locally recurrent or metastatic breast cancer\n\n          -  HER-2 negative or unknown\n\n          -  prior neo- and/or adjuvant anthracycline-based chemotherapy\n\n          -  measurable or non-measurable disease according to Response Evaluation Criteria In\n             Solid Tumors (RECIST) 1.0\n\n          -  adequate haematological, hepatic and renal functions\n\n          -  ECG without any clinically relevant abnormality\n\n        Exclusion Criteria:\n\n          -  known or clinical evidence of brain metastases or leptomeningeal involvement\n\n          -  history of  second primary malignancy\n\n          -  patients having as sole tumour lesion: malignant effusion, lymphangitis, cystic\n             lesion, bone lesion, and any other lesion not assessed by imaging techniques or\n             colour photography\n\n          -  pre-existing motor/ensory grade > 1 peripheral neuropathy\n\n          -  prior therapy with vinca alkaloids and/or gemcitabine\n\n          -  history of severe hypersensitivity to vinca alkaloids and/or gemcitabine or\n             contraindication to any of these drugs\n\n          -  pregnancy or breast feeding"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1004", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054338", 
            "org_study_id": "L00070 IN 303 B0", 
            "secondary_id": "2006-001139-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "vinflunine plus gemcitabine", 
                "intervention_name": "vinflunine 320 mg/m\u00b2 as a 20-minute infusion on day 1 of each cycle  repeated every 3 weeks gemcitabine 1000 mg/m\u00b2 IV on day 1 and 8 repeated every 3 weeks", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "vinflunine plus gemcitabine", 
                "description": "320 mg/m\u00b2 IV on day 1 plus gemcitabine 1000 mg/m\u00b2 on days 1 and 8 of each cycle repeated every 3 weeks", 
                "intervention_name": "vinflunine plus gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "paclitaxel plus gemcitabine", 
                "description": "paclitaxel 175 mg/m\u00b2 on day 1 plus gemcitabine 1250 mg/m\u00b2 on days 1", 
                "intervention_name": "paclitaxel plus gemcitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel", 
                "Vinblastine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 3, 2014", 
        "number_of_arms": "2", 
        "official_title": "Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Brazil: National Health Surveillance Agency", 
                "South Africa: Medicines Control Council", 
                "India: Drugs Controller General of India", 
                "Ukraine: State Pharmacological Center - Ministry of Health", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Czech Republic: State Institute for Drug Control", 
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: The Italian Medicines Agency", 
                "Peru: General Directorate of Pharmaceuticals, Devices, and Drugs", 
                "Portugal: INFARMED, National Authority of Medicines and Health Products, IP", 
                "Slovakia: State Institute for Drug Control"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "Every 6 weeks until disease progression"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054338"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months after disease progression"
            }, 
            {
                "measure": "Overall Response Rate & Disease Control Rate", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks"
            }, 
            {
                "description": "Collection and grading of reported adverse events and laboratory abnormalities", 
                "measure": "Adverse event profile", 
                "safety_issue": "Yes", 
                "time_frame": "Every 3 weeks"
            }, 
            {
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks"
            }
        ], 
        "source": "Pierre Fabre Medicament", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Medicament", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}